Neurocrine Biosciences vs Vertex Pharmaceuticals
Neurocrine Biosciences (NBIX) and Vertex Pharmaceuticals (VRTX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $15.2B
- Last close
- $150.57
- 12 months
- +8.3%
- Market value
- $142B
- Last close
- $515.02
- 12 months
- +21.9%
At a glance
- The biggest part of Vertex Pharmaceuticals's revenue is TRIKAFTA/KAFTRIO, 86% of the total in its last annual report.
- By market value, Vertex Pharmaceuticals ($141.7B) is about 9.3 times Neurocrine Biosciences ($15.2B).
- Over the last 12 months Neurocrine Biosciences's share price moved +8.3% and Vertex Pharmaceuticals's +21.9%; against the S&P 500 that is +2.6 points and +16.2 points.
- In their last fiscal years Neurocrine Biosciences kept 16.7% of revenue as net income and Vertex Pharmaceuticals 32.9%.
- In the last 90 days insiders reported 0 open-market purchases at Neurocrine Biosciences and 0 at Vertex Pharmaceuticals; members of Congress disclosed 0 trades in Neurocrine Biosciences and 1 in Vertex Pharmaceuticals.
- Next results: Neurocrine Biosciences Feb 9, 2027, Vertex Pharmaceuticals Feb 10, 2027.
How each one makes money: Neurocrine Biosciences revenue · Vertex Pharmaceuticals revenue
Share prices on one chart
Neurocrine Biosciences and Vertex Pharmaceuticals, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Neurocrine Biosciences NBIXNASDAQ · Biotechnology | Vertex Pharmaceuticals VRTXNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $15.2B | $142B |
| Revenue, last fiscal year | $2.86B | $12B |
| Net income, last fiscal year | $479M | $3.95B |
| Net marginNet income as a share of revenue | 16.7% | 32.9% |
| Free cash flow | $749M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Vertex Pharmaceuticals against
Common questions
How is Neurocrine Biosciences different from Vertex Pharmaceuticals?
Neurocrine Biosciences (NBIX) is in Biotechnology on NASDAQ, with $2.86B of revenue in its last fiscal year and a net margin of 16.7%. Vertex Pharmaceuticals (VRTX) is in Biotechnology on NASDAQ, with $12B of revenue in its last fiscal year and a net margin of 32.9%. The biggest part of Vertex Pharmaceuticals's revenue is TRIKAFTA/KAFTRIO, 86% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Neurocrine Biosciences and Vertex Pharmaceuticals compare in size?
Vertex Pharmaceuticals has the larger market value: Neurocrine Biosciences $15.2B and Vertex Pharmaceuticals $142B, at the last close.
Whose share price rose more over the last 12 months, NBIX or VRTX?
Over the last 12 months Neurocrine Biosciences moved +8.3% and Vertex Pharmaceuticals +21.9%. Past price moves say nothing about the future.
Which has had more insider buying, Neurocrine Biosciences or Vertex Pharmaceuticals?
Since 2006, Neurocrine Biosciences insiders reported 106 open-market purchases against 52 for Vertex Pharmaceuticals. These are counts of what was filed, not a view on either stock.
Do members of Congress trade NBIX or VRTX?
In the last 12 months, members of Congress disclosed 0 trades in Neurocrine Biosciences (NBIX) and 5 in Vertex Pharmaceuticals (VRTX).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Neurocrine Biosciences pageVertex Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/nbix-vs-vrtx







